NRG-LU007

Open to Accrual

Return to Protocol Table

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Principal Investigator

Quynh-Nhu Nguyen, MD,

Status

Open to Accrual

Date Opened To Accrual

August 17 2020

Disease Site

Lung [LU]

Small Cell

Phase

II/III

Developmental Therapeutics

Primary Objective

Phase II:

To compare investigator-assessed progression free survival (PFS) between atezolizumab plus radiotherapy and atezolizumab alone

Phase III:

To compare overall survival (OS) between atezolizumab plus radiotherapy and atezolizumab alone

Patient Population

Patients with pathologically proven diagnosis of extensive stage small cell lung cancer (ES-SCLC), stable disease (SD) or partial response (PR) after 4-6 cycles of etoposide/platinum (E/P) doublet plus atezolizumab

Target Accrual

324

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.